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Summary
Growth factors may enhance current cartilage repair techniques via multiple mechanisms including recruitment of chondrogenic cells (chemo-
taxis), stimulation of chondrogenic cell proliferation (mitogenesis) and enhancement of cartilage matrix synthesis. Two growth factors that have
been studied in cartilage repair are insulin-like growth factor (IGF) and platelet derived growth factor (PDGF). IGF plays a key role in cartilage
homeostasis, balancing proteoglycan synthesis and breakdown. Incorporating IGF into a ﬁbrin clot placed in an equine cartilage defect im-
proved the quality and quantity of repair tissue and reduced synovial inﬂammation. PDGF is a potent mitogenic and chemotactic factor for
all cells of mesenchymal origin, including chondrocytes and mesenchymal stem cells. Resting zone chondrocytes cultured with PDGF dem-
onstrated increased cell proliferation and proteoglycan production, while maturation of these cells along the endochondral pathway was in-
hibited. Pretreating chondrocytes with PDGF promotes heterotopic cartilage formation in the absence of any mechanical stimulus. PDGF
has also been shown to be a potent stimulator of meniscal cell proliferation and migration.
These studies and others suggest a potential role for these potent biological regulators of chondrocytes in cartilage repair. More work
needs to be performed to deﬁne their appropriate dosing and the optimum delivery method. Combining tissue growth factors with a biological
matrix can provide a physical scaffold for cell adhesion and growth as well as a means to control the release of these potent molecules. This
could result in biological devices that enhance the predictability and quality of current cartilage repair techniques.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Traumatic cartilage and meniscus injuries have limited ca-
pacity for repair due to the avascular nature of these tissues
and relatively low cell density. Left untreated, defects in the
cartilage layer often do not heal at all. Biochemical and
biomechanical tissue degradation ensues, leading to the
irreversible changes that characterize osteoarthritis. A num-
ber of tissue engineering approaches have been developed
which attempt to provide a foundation for cartilage repair.
Scaffolds may be implanted to allow existing cells from
the surrounding cartilage or synovium to migrate into the in-
jury site and form repair tissue. A supplemental source of
cells may be added prior to or at the time of scaffold implan-
tation in an attempt to insure that sufﬁcient repair tissue
forms and that the characteristics of the tissue closely re-
semble native hyaline cartilage. These techniques have
had variable success, however, because the neocartilage
often fails to completely ﬁll the defect, become integrated
with the surrounding tissue and effectively bear loads1.
The metabolism of mature articular cartilage is regulated
by a number of growth factors that originate from cellular
production within the cartilage, as well as from the synovial
ﬂuid and surrounding tissues. As the mechanisms of action
for these growth factors are established through well-deﬁned
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Received 20 October 2005; revision accepted 27 October 2005.40in vitro studies, it is becoming clear that growth factors may
eventually serve to augment current cartilage repair techni-
ques. Chemotactic growth factors may be used to encour-
age cell migration into an injury site. Cell numbers can be
increased and matrix production upregulated by the release
of appropriate local growth factors via scaffolds or other
methods of intra-articular delivery. The ability of two speciﬁc
cartilage growth factors, insulin-like growth factor (IGF) and
platelet derived growth factor (PDGF), to improve in vivo
cartilage and meniscus repair will be discussed in this
review.
Effects of IGF on cartilage repair
IGF is a circulating cytokine that reaches articular carti-
lage through the synovial ﬂuid. IGF is a single polypeptide
with protein sequencing similar to insulin. Two distinct forms
exist: IGF-1 with a molecular mass of 7.5 kDa and pI (iso-
electric point) of 8.5, and IGF-2 with a molecular mass of
7.4 kDa and pI of 7.02. IGF-1 is the most widely studied
form with respect to cartilage injury and repair.
IGF-1 is the main anabolic growth factor for articular car-
tilage. It plays a key role in cartilage homeostasis, balancing
proteoglycan synthesis and breakdown by the chondro-
cytes. In vitro studies demonstrate that IGF-1 stimulates
proteoglycan production in a dose-dependent manner, as
evidenced by increased [35S]-sulfate incorporation3. Simi-
larly, IGF-1 has been shown to slow proteoglycan catabo-
lism in a dose-dependent fashion4. Collagen production
and degradation do not appear to be regulated by IGF-1.3
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IGF-1 levels and chondrocyte responsiveness to IGF-1 pro-
gressively diminish with age5. This suggests that a simulta-
neous decrease in the amount of IGF-1 available and
a reduced ability for the cells to respond to the remaining
IGF may make cartilage less capable of maintaining its
structural and functional integrity. IGF nonresponsiveness
has been further observed to exist in chondrocytes from ar-
thritic cartilage or in the presence of inﬂammation2. The cel-
lular response to IGF-1 is receptor mediated and IGF
binding proteins in synovial ﬂuid appear to regulate the
amount of free IGF-1 that is available for receptor binding5.
The age-related decline in the responsiveness of chondro-
cytes to IGF-1 appears to be due at least in part to overex-
pression of IGF binding proteins. Chondrocytes from
patients with osteoarthritis have been observed to generate
excessive levels of IGF-1 binding proteins6,7. It has also
been suggested that a defect in IGF receptor binding or
postreceptor signaling may contribute to IGF nonrespon-
siveness in aged and arthritic cartilage2e4.
ACELLULAR REPAIR TECHNIQUES
In the absence of a supplemental source of chondrocytes
or precursors, cartilage repair is dependent on cellular re-
cruitment, retention and proliferation at the injury site. An
equine model has been developed to examine the effective-
ness of cartilage repair methods in large, clinically relevant
defects under high intra-articular loading conditions. Critical
size, full thickness defects, 15 mm in diameter and extend-
ing 1 mm or less into the subchondral bone, were arthro-
scopically created on the lateral trochlear ridge of the
distal femur of adult horses8. The defects were ﬁlled with ﬁ-
brin clots loaded with IGF-1. The treatment consisted of add-
ing 25 mg of the growth factor to 1.0 mL calcium-activated
thrombin during preparation of the ﬁbrin clot. Control defects
were ﬁlled with ﬁbrin clots alone. Timed IGF-1 release fromthe ﬁbrin clot was assumed to occur, although the release
kinetics were not characterized.
Analysis of the synovial ﬂuid and synovial membrane at
various interim time points showed a mild transient inﬂam-
matory reaction to the surgery, but no apparent reaction to
IGF-1. All defects were grossly observed to be ﬁlled with re-
pair tissue at 6 months, with the IGF-1 treated defects being
more completely ﬁlled and better attached to the subchon-
dral bone than the control defects (Fig. 1). Histological anal-
ysis indicated that the control defects contained poorly
organized collagen which was predominantly type I, with
pockets of type II collagen. Fibroblasts were the primary
cell type found in these defects. In contrast, IGF-1 treated de-
fects contained mainly chondrocytes in an organized colla-
gen matrix consisting predominantly of type II collagen.
Overall, IGF-1 treatment was found to signiﬁcantly improve
quantity and quality of defect repair tissue in this model.
The chemotactic effect of IGF-1 on the repair of partial
thickness defects created in healthy knee joint articular car-
tilage was also studied in skeletally mature rabbits and mini
pigs9. In rabbits, aggressive, rectangular defects 1 mm
wide, 0.2e0.25 mm deep and 4e6 mm long were created
in the patellar groove and the medial femoral condyle. Sim-
ilarly located defects in the mini pigs were 0.5 mm wide,
0.6 mm deep and 7e9 mm long. In an effort to render the
defect surfaces more favorable to cell adhesion, the defects
were brieﬂy exposed to chondroitinase ABC or trypsin to re-
move surface proteoglycans. A single application of IGF-1
(50 ng/mL) was then either administered topically to the sur-
face of the empty defect or added to a ﬁbrin clot that was
placed in the defect site. Based on defect volume, the total
dose of IGF-1 was approximately 40e75 ng in the rabbits
and 110e140 ng in the mini pigs. The effects of these treat-
ments on the repair process were examined at intervals out
to 48 weeks.
IGF-1 treatment resulted in an inconsistent but increased
number of mesenchymal cells present in the defect site at 5Fig. 1. Macroscopic appearance of control (A) and IGF-1 treated (B) cartilage defects in an equine model at 6 months post-op. Treated defects
were ﬁlled with a ﬁbrin clot supplemented with IGF-1 at the time of surgery. Control defects were ﬁlled with a ﬁbrin clot alone. IGF treatment
improves the quantity and quality of new cartilage ﬁlling the defect8.
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gested to be the synovial membrane and its underlying tis-
sues. The addition of the ﬁbrin clot enhanced the cell
density, although the repair cells eventually remodeled the
ﬁbrin matrix and replaced it with an avascular ﬁbrous tissue.
Good integration was seen at the defect margins in IGF-1
treated animals, with thin peripheral bands of differentiated
chondrocytes and hyaline-like cartilage present. Few chon-
drocytes appeared to migrate into the defect site, however,
despite the presence of the ﬁbrin scaffold. At 48 weeks, pre-
dominantly ﬁbrous connective tissue persisted in all defects
treated with IGF-1 in the rabbits and the mini pigs. The re-
duced effectiveness of IGF-1 treatment in this study, as
compared to the results obtained in the equine model,
may be related to the lower total dose of IGF used in rabbits
and mini pigs and the absence of a carrier scaffold.
CELL-BASED REPAIR TECHNIQUES
A second study using the full thickness defect model in
horses, previously described, demonstrated that IGF-1
may also be used to enhance cell-based cartilage repair10.
In this case, chondrocytes were isolated from the patellofe-
moral cartilage of immature horses and expanded in cul-
ture. The control and IGF-1 loaded (25 mg/defect) ﬁbrin
clots were prepared as before, with 20 106 cells added
to all clots immediately before implantation into mature
horses.
Synovial ﬂuid analysis indicated that early white blood
cell counts were reduced in the IGF-1 treated joints, sug-
gesting that there may have been a decreased postopera-
tive inﬂammatory response. The histological score for thesynovial membrane was also signiﬁcantly better for the
IGF-1 treated joints as compared to the controls, further
demonstrating that IGF-1 may have reduced the effects of
inﬂammation. Quantitative gross assessment scores at
8 months were signiﬁcantly better for the IGF-1 treated
defects as compared to the control defects (Fig. 2). The
addition of IGF-1 improved the overall continuity and
consistency of the repair tissue. IGF-1 treated defects ap-
peared to be more completely ﬁlled with repair tissue, better
integrated with the surrounding host tissue than the controls
and exhibited less surface ﬁbrillation.
Although the mean cartilage histological scores for the
control and IGF-1 treated defects were not statistically dif-
ferent, it appeared that the addition of IGF-1 to a cell-seed-
ed ﬁbrin scaffold improved the quality of the resulting repair
tissue. The cellularity and pattern of cell distribution in repair
tissue for IGF-1 treated defects appeared to be more orga-
nized and less like ﬁbrous tissue than the control joints. To-
luidine blue matrix staining for extracellular proteoglycan
distribution was signiﬁcantly improved for the IGF-1 treated
defects. In addition, there was a trend toward greater type II
collagen gene expression in the IGF-1 treated lesions. How-
ever, there were no statistically signiﬁcant differences in
DNA content, hydroxyproline content or measured proteo-
glycan content in the repair tissue for treated and control
joints.
INTRA-ARTICULAR INJECTION
Since growth factors have short biological half-lives, it
may be necessary to provide extended exposure in order
to sufﬁciently stimulate cellular repair activities. The effectFig. 2. Histological appearance of cell-seeded cartilage defects in an equine model at 8 months post-op. Treated defects were ﬁlled with a ﬁbrin
clot seeded with chondrocytes and supplemented with IGF-1. Control defects were ﬁlled with a similarly seeded clot without the growth factor.
Hematoxylin and eosin staining of entire control defect (A) and IGF-1 treated defect (B) demonstrates slightly improved ﬁll in the treated de-
fects. Comparison of toluidine blue staining of control tissue (C) and treated (D) repair tissue shows a signiﬁcant increase in staining intensity
in IGF-1 supplemented repair tissue10 (A, B bar¼ 5 mm; C, D bar¼ 80 mm).
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ing was studied in rabbits implanted with osmotic drug
pumps11. Full thickness defects 1.2 mm wide and 8 mm
long were created on the femoral condyles of adult rabbits,
without disrupting the subchondral bone. No scaffold or cell
supplementation was provided within the defect. IGF-1 or
a control solution (saline) was delivered directly into the joint
space for up to 8 weeks. The daily delivery volume was
62 mL, which corresponded to a daily dose of 30 ng of
IGF-1. Growth factor treatment at this dose level produced
no signiﬁcant improvement in cell number or proteoglycan
synthesis in the defect, or in the amount or quality of repair
tissue that ﬁlled the defect.
The therapeutic value of periodic, low dose IGF-1, intra-ar-
ticular injections into osteoarthritic knee and temporoman-
dibular joints in mice was also found to be ineffective12.
The effects of IGF-1 administration on the cartilage morphol-
ogy, as well as the anabolic and mitogenic activity of the
chondrocytes, weremeasured. Serial 60 mL intra-articular in-
jections of IGF-1 (25 ng/60 mL) were made in 20-month-old
mice every 3 days for a total of 9 days. IGF-1 treatment slightly
increased DNA content and proteoglycan content, as com-
pared to untreated controls. Acid phosphatase activity was
also moderately increased, while alkaline phosphatase ac-
tivity was signiﬁcantly reduced. These results indicate that
short-term exposure to the growth factor increased the met-
abolic activity of the chondrocytes. It is unknownwhether this
effect is sustained after the treatment is terminated.
Similarly, IGF-1 alone failed to slow or reverse ongoing
cartilage degeneration in a canine anterior cruciate ligament
(ACL) deﬁcient model (PondeNuki model) of osteoarthri-
tis13. Ligament transection was performed and the animals
received no treatment for 3 weeks. Intra-articular injections
of 1 mg of IGF-1 were then administered three times
a week for the next 3 weeks. At the conclusion of the study,
the damage to the condylar cartilage for the IGF-1 treatment
group was extensive and indistinguishable from the osteoar-
thritic group that received no treatment. Tissue protease lev-
els for IGF-1 treated cartilage were more similar to
osteoarthritic cartilage than normal cartilage. The uronic
acid and hydroxyproline content were somewhat elevated
relative to arthritic cartilage, but less than normal levels.
When intra-articular IGF-1 treatment was coupled with sys-
temic doses of polysulfated polysaccharide (PPS), however,
a signiﬁcant decrease in cartilage degradation was seen.
This suggests that PPS may inhibit synthesis of proteases
that degrade IGF-1 or its receptor, or affect its binding pro-
tein. Therefore, more IGF-1 may be able to reach the chon-
drocytes and an enhanced repair response is achieved.
Effects of PDGF on cartilage repair
PDGF is a locally produced and locally acting growth fac-
tor. It is synthesized by smooth muscle cells, ﬁbroblasts, en-
dothelial cells and macrophages and stored primarily in
platelets14. PDGF consists of two distinct disulﬁde linked
peptide chains, A and B, which share a 60% protein se-
quence identity. The growth factor can be expressed as
a homodimer (PDGF-AA or PDGF-BB) or as a heterodimer
(PDGF-AB), with a molecular mass of approximately
30 kDa.
PDGF plays a fundamental role in the wound healing cas-
cade. It is present in high concentrations in platelets and in
the ﬂuids generated during the early stage of wound heal-
ing15. PDGF is a potent mitogenic and chemotactic factor
for cells of mesenchymal origin, including ﬁbroblasts,osteoblasts and chondrocytes, and is thus believed to be
capable of enhancing tissue regeneration and repair.
PDGF receptors have been identiﬁed on a number of cell
types including chondrocytes and the number of receptors
is upregulated by the presence of inﬂammatory cytokines
such as interleukin-1 (IL-1)16.
Indirect evidence for the role of PDGF and other growth
factors active in the wound healing process can be seen
from the healing response in cartilage defects treated with
microfracture. This procedure involves creating microperfo-
rations in the subchondral bone with an arthroscopic awl in
and around a chondral lesion17. The mechanical integrity of
the bone is maintained through careful placement of the
holes. The awl is driven to a depth of 2e4 mm to insure
that the marrow space is accessed and bleeding is ob-
served. A clot forms in the defect, which is anchored to
the bone by the increased surface roughness produced
by the microperforations. Growth factors such as PDGF
are released into the defect site, exerting chemotactic and
mitogenic effects on cells in the surrounding cartilage and
inﬁltrating mesenchymal stem cells. This provides an en-
riched environment for new tissue formation which may
be augmented by placement of a scaffold seeded with au-
tologous cells18,19.
CHONDROCYTE PROLIFERATION AND MATURATION ASSAY
The effect of PDGF-BB on chondrocytes was investigated
by exposing conﬂuent cultures of rat costochondral resting
zone chondrocytes to a range of doses of PDGF-BB and
culture times20. At conﬂuence, cells were incubated with 0,
2.3, 4.7, 9.5, 19, 37.5, 75, 150 and 300 ng/mL for 24 h.
Time course studies were also performed, where conﬂuent
cultures were exposed to either 37.5 or 150 ng/mL for
1e10 days with media changed every second day. Cultures
were assayed for cell proliferation via cell number and [3H]-
thymidine incorporation, alkaline phosphatase speciﬁc activ-
ity via p-nitrophenol release, proteoglycans synthesis via
[35S]-sulfate incorporation, matrix protein synthesis by [3H]-
proline incorporation, and resting zone chondrocyte differen-
tiation by monitoring responsiveness to vitamin D
metabolites.
Increased proliferation of chondrocytes was observed
with concentrations of PDGF-BB from 4.7 to 300 ng/mL
with a maximum number of cells at 75 ng/mL. [3H]-Thymi-
dine incorporation was increased at all concentrations ex-
amined as compared to controls. Longer-term exposure to
PDGF-BB resulted in increased cell numbers but the effect
decreased over time and at 10 days, PDGF-BB treated cells
were not signiﬁcantly different from untreated controls.
Long-term exposure to PDGF-BB inhibited alkaline phos-
phate speciﬁc activity, particularly at the 150 ng/mL dose,
while short-term incubation at all concentrations of PDGF-
BB had no effect20. PDGF-BB stimulated proteoglycan pro-
duction 2.5e3.5 fold in a dose-dependent manner (Fig. 3).
In addition, PDGF-BB had no effect on [3H]-proline incorpo-
ration, indicating no change in collagen production.
Strikingly, PDGF-BB treatment inhibited the maturation of
the resting zone chondrocytes20. Cells maintained their
chondrocytic phenotype compared with controls. These re-
sults indicate that PDGF-BB has a direct effect on chondro-
cytes isolated from growth plate cartilage. Exposure to
PDGF-BB in culture appears to increase cell proliferation
and cartilage proteoglycan production, while preventing pro-
gression of cell maturation along the endochondral pathway.
In order to ﬁll a defect site with cartilage, it is important that
the chondrocytes should be capable to some extent of
407Osteoarthritis and Cartilage Vol. 14, No. 5both proliferation and differentiation. This is particularly criti-
cal at the interface of the cartilage and subchondral bone to
prevent delamination of the repair tissue. Terminal chondro-
cyte differentiation, as evidenced by matrix mineralization,
should be minimized for a chondrogenic implant in the joint
space to prevent osteophyte formation.
HETEROTOPIC CARTILAGE FORMATION ASSAY
The effect of pretreatment with PDGF-BB on the ability of
costochondral cells to form heterotopic cartilage was inves-
tigated to potentially develop a readily available source of
chondrocytes for cartilage repair21. Cells were isolated
from the rib tissue of adult rats and expanded in culture. Con-
ﬂuent cultures were then incubated in media containing
37.5 ng/mL PDGF-BB for 4 or 24 h. The cells were subse-
quently seeded onto scaffolds made from polylactic acid
(PLA)/polyglycolic acid (PGA) copolymer foams. Controls
consisted of scaffolds loaded with cells without growth factor
pretreatment and scaffolds without cells. The scaffolds were
implanted intramuscularly in nude mice and the chondrocyte
response was evaluated at 4 and 8 weeks postoperatively.
Histological analysis revealed that cartilage was present
in all scaffolds at 4 and 8 weeks. The amount of newly
formed cartilage varied signiﬁcantly with the pretreatment
duration, as well as postoperative time. At 4 weeks, cells
pretreated with PDGF-BB for 4 or 24 h produced less carti-
lage than untreated cells (Fig. 4). But by 8 weeks, the
amount of cartilage produced by the pretreated cells was
signiﬁcantly increased as compared to the untreated control
cells. The longer pretreatment with PDGF-BB was found to
be detrimental, however. Cells pretreated for 24 h produced
42% less cartilage at 8 weeks than cells pretreated for 4 h.
The results of this study indicate that short-term pretreat-
ment with PDGF-BB can promote heterotopic formation of
cartilage by costochondrocytes at 8 weeks in the absence
of any mechanical stimulus. PDGF also caused increased
proliferation and extracellular matrix sulfation without caus-
ing an increase in alkaline phosphatase, indicating that the
cells remained in a less differentiated state. This effect may
play a role in the reduced amount of cartilage seen at 4
weeks. By 8 weeks, chondrogenesis was increased, possi-
bly due to the increased pool of chondrocytes with the rest-
ing zone phenotype21.
Fig. 3. [35S]-Sulfate incorporation of conﬂuent cultures of resting zone
chondrocytes demonstrates a dose-dependent response, following
treatment with PDGF-BB for 24 h. Values are the mean  S.E.M.
of six cultures, *P< 0.05, treatment vs control20.INTRA-ARTICULAR INJECTION
The safety of repeated PDGF-BB injections on healthy
knee joint cartilage and subchondral bone growth was in-
vestigated in skeletally immature rats22. Short-term effects
were examined by giving the animals intra-articular injec-
tions of PDGF-BB (0.5 or 0.75 mg/injection) for 5 consecu-
tive days. Histological samples were then collected at
intervals from 7 to 35 days. Long-term effects were deter-
mined by administering injections of 0.5 mg PDGF-BB for
5 days, then 0.2 mg daily for 5 or 10 days. The injection se-
ries was then repeated on days 30, 45, 90 and 180.
No gross changes to the knees injected with PDGF-BB
were noted for the short-term and long-term treatments.
No changes in chondrocyte morphology were observed
and there was no evidence of ﬁbrosis or inﬂammatory cells.
A minor transient increase in osteogenic activity was fre-
quently noted in the subchondral bone following the series
of PDGF-BB injections. PDGF-BB treatment also induced
one incident of heterotopic cartilage formation in the patellar
tendon and one incident of ossicle formation. Overall,
PDGF-BB was found to be safe and well tolerated by young
rat joint cartilage.
Growth factors and meniscus repair
The importance of the meniscus to normal knee joint
function is well established. The meniscus provides load
transmission across the joint, as well as shock absorption,
stability and lubrication. Injuries to the meniscus are com-
mon and usually related to excessive torsional loading.
Complete removal of the meniscus following injury results
in accelerated cartilage degeneration due to the signiﬁcant
increase in contact stress. Even partial meniscectomy is ac-
knowledged to be detrimental to joint cartilage and therefore
methods to reconstruct and repair the meniscus continue to
be developed.
The ability of the meniscus to heal is highly dependent on
the location of the injury. The inner two-thirds of the menis-
cus has relatively low vascularity and cellularity, and thus
does not heal well. Injuries to the peripheral, more highly vas-
cularized region, have a more favorable prognosis. Growth
factors and cytokines present in blood may in part be
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Fig. 4. The effect of PDGF-BB pretreatment of resting zone chon-
drocytes on heterotopic cartilage formation (*P< 0.05, all groups
vs implant alone, #P< 0.05, 4 vs 8 weeks, CP< 0.05 PDGF-BB
treatment for 24 vs 4 h)21.
408 M. B. Schmidt et al.: Effects of IGF and PDGF on cartilage repairresponsible for the superior healing of meniscal tears in the
peripheral region. Potentially, growth factors may be used
therapeutically to stimulate proliferation of ﬁbrochondrocytes
in a meniscus injured in the avascular region, as well as mi-
gration of cells to the injury site. This concept has been ex-
plored to a limited extent in vitro with variable results.
RESPONSE VS LOCATION
The in vitro response of bovine meniscal ﬁbrochondro-
cyte cells to PDGF-AB and IGF-1 has been compared for
different regions of the meniscus23. Cells were isolated
from the peripheral vascular region, the intermediate region
and the inner avascular region. The effect on DNA synthe-
sis was determined for growth factor concentrations of 0.1,
1.0, and 10 ng/mL. The chemotactic response was mea-
sured in cell migration studies using collagen coated che-
motaxis chambers and growth factor concentrations of 1,
10, and 100 ng/mL. The upper chamber contained cells
suspended in medium and no growth factor, while the lower
chamber contained medium with growth factor. The number
of cells that migrated through the separating membrane
was then counted as a measure of the chemotactic effect
of the growth factor.
PDGF-AB was found to stimulate DNA synthesis in cells
from all three regions of the meniscus in a dose-dependent
manner, with maximal stimulation at the highest concentration
of 10 ng/mL. PDGF-AB also stimulated migration of meniscal
cells from all regions with a maximum effect at 10 ng/mL.
Migration appeared to be inhibited above this concentration.
In contrast, IGF-1 had no signiﬁcant effect on DNA synthesis
at any of the concentrations studied. Signiﬁcant IGF-
induced chemotaxis was seen at 100 ng/mL only for cells
isolated from the middle and inner zones. The results
from this study indicate that PDGF-AB is a potent stimulator
of meniscal cell proliferation and migration, while IGF-1 is
not as effective.
A similar comparison of the mitogenic response to PDGF-
AB in the peripheral and intermediate regions was per-
formed using lateral and medial sheep menisci15. Menisci
were sectioned vertically and explanted sections were cultured
up to 4 days with 1e200 ng/mL PDGF-AB. Autoradiographic
results showed increased DNA content for PDGF-AB
treated tissue in both the peripheral region and the interme-
diate region. There were signiﬁcantly more labeled cells
present in the peripheral region, as compared to the inter-
mediate region, for all growth factor concentrations. In this
study, a dose of 100 ng/mL PDGF-AB produced maximal
increase in DNA content in the peripheral region. No statis-
tical differences in the response were observed between
the lateral and medial menisci.
EFFECT OF MECHANICAL STIMULATIONþGROWTH FACTORS
The effects of static compressive loading coupled with
PDGF-AB or IGF-1 on matrix production were studied in bo-
vine meniscal tissue explants24. Full thickness cores were
obtained from the intermediate partially vascularized region
of immature bovine menisci. These cores were sectioned
and the sections were placed individually in culture. The ef-
fects of growth factor dose on newly synthesized proteins
(primarily collagen) and proteoglycans were examined, as
well as the temporal effects at a single concentration. The
interaction between chemical and mechanical stimuli was
explored by applying static compressive loads sufﬁcient to
achieve 25% and 50% deformation for 4 days.PDGF-AB had a signiﬁcant stimulatory effect on matrix
production with maximal stimulation of matrix production
at 100 ng/mL. IGF-1 was also found to stimulate matrix syn-
thesis with maximally effective dose at 300 ng/mL. IGF-1
generally had a weaker stimulatory effect than PDGF-AB.
Signiﬁcant and sustained stimulation of proteoglycan syn-
thesis was seen for both PDGF-AB and IGF-1 (Fig. 5), al-
though in this study neither growth factor treatment
signiﬁcantly affected DNA content. Static compressive load-
ing had an inhibitory effect on matrix production for both
growth factors and at both levels of compression. This result
suggests that PDGF especially enhances a beneﬁcial effect
on healing of meniscal injuries and the in vivo studies of
growth factor enhanced meniscal repair may be affected
by joint loading patterns and animal activity levels.
Animal models for cartilage repair
Evaluation of potential cartilage repair techniques re-
quires the choice of an appropriate in vivo articular defect
model. Unfortunately, due to the physiological and anatom-
ical differences between human joints and those of experi-
mental animals, there is no animal defect that perfectly
models human cartilage injuries.
The size of the defect relative to the overall size of the
joint must be carefully considered when planning a cartilage
repair study. Creation of critical size defects is important,
since variable and spontaneous healing in noncritical de-
fects does not provide a proper control for comparison.
But the effects of oversized defects must also be consid-
ered. For example, the defects created in the two rabbit
studies summarized in this review were 1e1.2 mm wide
and 6e8 mm long, representing a considerable proportion
of the knee joint surface area for these animals8,11. The re-
moval of an excessive number of native cells and destruc-
tion of the intrinsic mechanical integrity of the remaining
cartilage may make tissue regeneration in these large de-
fect sites extremely challenging.
The location of the defect on the joint surface is another im-
portant factor that inﬂuences cartilage repair. The stress dis-
tribution on the surface of the knee joint, for example, varies
signiﬁcantly with different animal species. In order to approx-
imate cartilage injuries that often occur in highweight bearing
areas on human knee condyles, for example, defects should
be positioned at the appropriate location that corresponds to
this condition for the species. An advantage of very large
quadruped animal models, such as the previously described
horsemodel, is that relatively large defects can be easily cre-
ated in most locations on the knee surface.
The penetrating depth of the cartilage defect signiﬁcantly
inﬂuences healing and generation of repair tissue. Defects
can be divided into three depth categories: (1) partial thick-
ness defects, in which the defect is entirely contained in the
cartilage layer; (2) full thickness defects, in which the defect
extends down to, but not into, the subchondral bone; and
(3) osteochondral defects which extend into the subchon-
dral bone25. Cartilage repair is generally minimal in partial
or full thickness defects that are wholly contained in the car-
tilage layer because there is no contribution from vascular
elements3. Perforating the subchondral bone results in
bleeding, inﬂux of marrow cells and clot formation at the de-
fect site. Circulating cytokines, a supplemental source of
mesenchymal cells and a natural scaffold enrich the defect
site and enhance the healing process.
Finally, most cartilage repair investigations utilize acute
defects, which are surgically created and treated in the
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Fig. 5. Doseeresponse results for proteoglycan synthesis in meniscal explants exposed to IGF-1 (A) and PDGF-AB (B). Explants were sub-
jected to static compressive loads for 4 days. Data are normalized to basal medium (BSA) control values. Star denotes that the value is sig-
niﬁcantly different from the BSA controls (P< 0.05). Both growth factors stimulated proteoglycan synthesis, with PDGF-AB exhibiting
a stronger effect24.same procedure. But many patients seeking clinical treat-
ment present with persistent joint pain caused by chronic
cartilage injuries and degradation. Therefore, the age of
the defect and the development of prior degenerative
changes are important considerations for in vivo study de-
sign. Using multiple surgeries, a defect can be created
and left untreated for a period of time before intervention,
initiating changes in the joint environment that are analo-
gous to chronic defects25. Alternatively, an established
model of osteoarthritis, such as the PondeNuki, ACL-deﬁ-
cient canine model26, may be utilized in conjunction with
a cartilage defect. This combination may provide a better
representation of the clinical condition.
Carrier materials for growth factor delivery
Growth factors are made up of soluble proteins of rela-
tively small molecular mass that are rapidly absorbed or de-
graded. It is assumed that sustained release is required to
make them available to cells in sufﬁcient quantity and for
sufﬁcient duration to be of therapeutic value, although there
is little data available on the effects of release kinetics. Fur-
thermore, the optimum release proﬁle is likely to differ de-
pending on the speciﬁc action of the particular growth
factor. For example, it may be advantageous to release
chemotactic agents rapidly in the initial phase of the repair
process to recruit the cells needed to lay down the repair tis-
sue. Mitogenic agents, in contrast, may need to be released
over a longer period to insure that the repair tissue ade-
quately ﬁlls and matures within the defect.
Native or synthetic carrier materials may be used for car-
tilage repair, depending on the mechanical demands of the
defect site and the rate of degradation required. Native
materials offer the advantage of typically providing excellent
biocompatibility and optimal surface properties for cell at-
tachment and ingrowth. But the ability to control growth fac-
tor loading and release from native materials such as ﬁbrin,
collagen, hyaluronic acid (HA) and demineralized bone ma-
trix may be limited by the sensitivity of these materials to
processing conditions, as well as the nature and extent of
the physical and chemical interactions which occur with
the growth factors. In contrast, degradable, synthetic poly-
mers, such as the PLA/PGA copolymer used for the hetero-
topic cartilage formation assay discussed previously21, mayoffer tailorable growth factor release and carrier degradation
proﬁles due to the wide variety of ways these polymers can
be processed.
Discussion
The effects of IGF and PDGF on cartilage and meniscus
repair are summarized in Figs. 6 and 7. These growth fac-
tors offer a promising way to augment existing cartilage re-
generation techniques by stimulating cell migration to the
wound site, cell proliferation and matrix production. The cor-
rect balance of these repair activities must be achieved in
order for biologically and mechanically functional tissue to
be successfully formed. The role of growth factors in regu-
lating the metabolic balance is now beginning to be under-
stood. Systematic in vitro studies have allowed the cellular
responses to speciﬁc growth factors to be characterized
without the complicated biological interactions that exist in
the in vivo environment, the effects of mechanical stress,
and the limited half-life of most growth factor peptides. How-
ever, a more comprehensive understanding of the effect of
growth factors on the in vivo enhancement of the cartilage
repair process is needed.
Variable results for growth factor treatments are still
commonly reported for in vivo cartilage repair studies. For
example, defects within the cartilage layer treated with ﬁbrin
clots loaded with IGF-1 were ﬁlled by predominantly ﬁbrous
tissue in rabbits and mini pigs, but well-organized tissue
resembling hyaline cartilage was observed in the horse
model. The more favorable outcome in the latter study may
be due in part to the increased IGF-1 dose and concentration
within the defect, as compared to smaller animal models
(Table I). But the optimum amount of IGF-1 for successful
cartilage repair may in fact be more dependent on factors
such as load bearing and defect characteristics than on the
size of the animal. The dose adjustments that are traditionally
made relative to body weight for systemically administered
substances may not be applicable when dealing with locally
applied and locally acting growth factors. It is also possible
that upregulating proteoglycan synthesis through IGF-1
treatment alone is insufﬁcient to generate adequate repair
tissue for some defect sizes and geometries.
Published data on the use of intra-articular injections of ei-
ther IGF-1 or PDGF-BB alone are relatively scant. The three
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Intra-articular IGF injection:
In vitro cellular response to IGF:
•       Stimulates proteoglycan synthesis in cultured chondrocytes
        and meniscal explants
•       Slows proteoglycan catabolism in cartilage
•       Increases cell migration in the partially vascular and avascular
        regions of the meniscus
•       Slightly increases in proteoglycan content in cartilage
•       Decreases cartilage degradation when coupled with
        polysulfated polysaccharide
•       Improves full thickness defect fill with hyaline-like repair tissue
•       Reduces synovial inflammation
•       Improves tissue integration
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Fig. 6. Summary of the in vitro and in vivo effects of IGF on cartilage and meniscal repair.studies of IGF-1 reviewed here demonstrated little therapeu-
tic effect of these treatments for cartilage repair in osteoar-
thritic joints in mice12 and dogs13 and in a cartilage defect
model in rabbits11. The data are limited to only these models
and dosages. In a study utilizing normal, immature rat
knees22, repeated injections of PDGF-BBwere demonstrated
to be safe at the given dosing regimen. No gross changes
to the chondrocytes occurred, no accumulation of ﬁbroblastsor inﬂammatory cells was observed in the joint space and no
effect on subchondral bone growth was detected. Although
the effectiveness of PDGF injections on cartilage repair
was not examined, PDGF-BB has been shown to stimulate
resting zone chondrocytes in vitro, increasing proliferation
and inhibiting maturation of these cells22.
To date, no detailed studies optimizing the dose, injection
regimen, or combinations of factors in cartilage repairIn vivo heterotopic cartilage formation:
Increases cartilage present in intramuscular scaffolds seeded
with cells pretreated with PDGF
Intra-articular PDGF injection:
Safety demonstrated in repeated injections in healthy joints of
rats; no gross changes in cartilage appearance or fibrosis
In vitro cellular response to PDGF:
Increases chondrocyte proliferation
Upregulates proteoglycan synthesis in cultured chondrocytes
and meniscal explants
Inhibits maturation of resting zone chondrocytes
Increases meniscal cell proliferation and migration
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Fig. 7. Summary of the in vitro and in vivo effects of PDGF on cartilage and meniscal repair.
411Osteoarthritis and Cartilage Vol. 14, No. 5models have been published. More extensive research is
needed before the clinical beneﬁts of injections of IGF-1
or PDGF-BB into the joint space can be clearly delineated.
Injectable carriers may need to be developed to provide
controlled release of growth factors into the joint space. It
is well known that the biological half-lives of most growth
factor peptides are very short and this may limit the effec-
tiveness of the current intra-articular injection therapies.
Combining a growth factor with HA, for example, allows for
a more prolonged delivery of the growth factor, potentially
enhancing this widely-used clinical treatment for cartilage
degeneration and joint pain. HA gels have been prepared
as injectable carrier vehicles for growth factors and bioactivity
assays demonstrate that sustained release is achieved over
periods as long as 10e15 days27.
Loading growth factors onto a carrier material may also of-
fer a better method to enhance the consistency and quality of
current cell-based and acellular cartilage defect repair tech-
niques. PDGF has been incorporated into polymerized HA
scaffolds, showing uniform distribution and good retention.
Increased cell proliferation on the growth factor-loaded ma-
trix was observed, as compared to untreated controls28,29.
Pretreating cells with growth factors prior to implantation
into the wound site represents an alternative approach that
can be used to jump-start the repair process. Once a thor-
ough understanding of in vivo growth factor actions, dosing
requirements and optimum exposure rates is achieved,
growth factor treatment may provide a valuable tool to control
and improve the cartilage repair and healing process.
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